News
VRDN
22.73
-1.90%
-0.44
Weekly Report: what happened at VRDN last week (0831-0904)?
Weekly Report · 2d ago
Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
Barchart · 09/02 15:00
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), Teladoc (TDOC) and Protagonist Therapeutics (PTGX)
TipRanks · 09/01 12:10
Weekly Report: what happened at VRDN last week (0824-0828)?
Weekly Report · 08/31 09:42
Weekly Report: what happened at VRDN last week (0817-0821)?
Weekly Report · 08/24 09:43
Analysts Offer Insights on Healthcare Companies: Health Catalyst (HCAT) and Viridian Therapeutics (VRDN)
TipRanks · 08/20 13:40
Weekly Report: what happened at VRDN last week (0810-0814)?
Weekly Report · 08/17 09:43
Stifel Nicolaus Reaffirms Their Buy Rating on Viridian Therapeutics (VRDN)
TipRanks · 08/13 15:36
Viridian Therapeutics (VRDN) Gets a Buy from Truist Financial
TipRanks · 08/13 02:26
Viridian Therapeutics (VRDN) Receives a Buy from Evercore ISI
TipRanks · 08/10 12:45
Weekly Report: what happened at VRDN last week (0803-0807)?
Weekly Report · 08/10 09:40
Viridian Therapeutics Is Maintained at Outperform by RBC Capital
Dow Jones · 08/07 20:35
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $36
Benzinga · 08/07 20:25
Viridian Therapeutics price target raised to $39 from $38 at Truist
TipRanks · 08/07 14:25
Viridian Therapeutics Price Target Raised to $39.00/Share From $38.00 by Truist Securities
Dow Jones · 08/07 13:37
Viridian Therapeutics Is Maintained at Buy by Truist Securities
Dow Jones · 08/07 13:37
Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $39
Benzinga · 08/07 13:27
Viridian Therapeutics price target raised to $36 from $35 at RBC Capital
TipRanks · 08/07 12:37
Truist Financial Reaffirms Their Buy Rating on Viridian Therapeutics (VRDN)
TipRanks · 08/07 12:09
RBC Capital Sticks to Their Buy Rating for Viridian Therapeutics (VRDN)
TipRanks · 08/07 11:08
More
Webull provides a variety of real-time VRDN stock news. You can receive the latest news about Viridian Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About VRDN
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. It is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.